Healthcare -
Medical - Instruments & Supplies - NASDAQ - US
$ 34.94
-0.143 %
$ 1.73 B
Market Cap
-43.05
P/E
1. INTRINSIC VALUE
Balance Sheet
AtriCure, Inc.
| Current Assets | 268 M |
| Cash & Short-Term Investments | 123 M |
| Receivables | 60.3 M |
| Other Current Assets | 84.8 M |
| Non-Current Assets | 342 M |
| Long-Term Investments | 0 |
| PP&E | 47.4 M |
| Other Non-Current Assets | 294 M |
| Current Liabilities | 73.4 M |
| Accounts Payable | 25 M |
| Short-Term Debt | 2.8 M |
| Other Current Liabilities | 45.6 M |
| Non-Current Liabilities | 74.9 M |
| Long-Term Debt | 61.9 M |
| Other Non-Current Liabilities | 13.1 M |
EFFICIENCY
Earnings Waterfall
AtriCure, Inc.
| Revenue | 465 M |
| Cost Of Revenue | 118 M |
| Gross Profit | 348 M |
| Operating Expenses | 388 M |
| Operating Income | -40 M |
| Other Expenses | 4.68 M |
| Net Income | -44.7 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
AtriCure, Inc.
| Net Income | -44.7 M |
| Depreciation & Amortization | 18.7 M |
| Capital Expenditures | -23.5 M |
| Stock-Based Compensation | 0 |
| Change in Working Capital | 0 |
| Others | 12.2 M |
| Free Cash Flow | -11.3 M |
Wall Street Analysts Price Targets
AtriCure, Inc.
Wall Street analysts predict an average 1-year price target for ATRC of $39.7 , with forecasts ranging from
a
low of
$26 to a high of $53 .
ATRC Lowest Price Target
Wall Street Target
26 USD
-25.59%
ATRC Average Price Target
Wall Street Target
39.7 USD
13.53%
ATRC Highest Price Target
Wall Street Target
53 USD
51.69%
4. DIVIDEND
ANALYSIS
ATRC does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
AtriCure, Inc.
Sold
0-3 MONTHS
83.6 K USD 1
3-6 MONTHS
233 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
84.2 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference. AtriCure's management is scheduled to host a fireside chat on Monday, June 9, 2025, at 4:00 p.m. Eastern Standard Time. Interested parties may acc.
businesswire.com
- 3 weeks ago
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect?
The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
- 1 month ago
AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity Matthew O'Brien - Piper Sandler Companies John McAulay - Stifel Financial Corp. Lily Lozada - JPMorgan Chase & Co. Marie Thibault - BTIG, LLC Danny Stauder - Citizens JMP Securities, LLC Mike Matson - Needham & Company, LLC Danielle Antalffy - UBS Group AG Suraj Kalia - Oppenheimer & Co. Inc. Operator Good afternoon, and welcome to AtriCure's First Quarter 2025 Earnings Conference Call. This call is being recorded for replay purposes.
seekingalpha.com
- 1 month ago
AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
- 1 month ago
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
AtriCure (ATRC) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.
zacks.com
- 1 month ago
AtriCure Reports First Quarter 2025 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2025 financial results. “Our performance in the first quarter reflects outstanding execution of several new product launches and the strength of our overall business,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “As.
businesswire.com
- 1 month ago
AtriCure to Announce First Quarter 2025 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2025 financial results on Tuesday, April 29, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, April 29, 2025, to discuss its first quarter 2025 financial results. Those interested in list.
businesswire.com
- 2 months ago
AtriCure to Host Analyst & Investor Day on March 26, 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to 4:00 pm ET. “Our team is excited to highlight our leading portfolio of products and innovative pipeline for market expa.
businesswire.com
- 3 months ago
AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
- 4 months ago
AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lily Lozada - JPMorgan William Plovanic - Canaccord Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Rick Wise - Stifel Mike Matson - Needham & Company Danny Stauder - Citizens JMP Danielle Antalffy - UBS Suraj Kalia - Oppenheimer Matthew O'Brien - Piper Sandler Operator Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded for replay purposes.
seekingalpha.com
- 4 months ago
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
- 4 months ago
AtriCure (ATRC) Reports Q4 Loss, Lags Revenue Estimates
AtriCure (ATRC) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.21 per share a year ago.
zacks.com
- 4 months ago
8. Profile
Summary
AtriCure, Inc. ATRC
COUNTRY
US
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 1.73 B
Dividend Yield
0.00%
Description
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Contact
7555 Innovation Way, Mason, OH, 45040
https://www.atricure.com
IPO
Date
Aug. 5, 2005
Employees
1300
Officers
Mr. Salvatore Privitera J.D.
Chief Technical Officer
Ms. Angela L. Wirick
Chief Financial Officer
Mr. Justin J. Noznesky
Chief Marketing & Strategy Officer
Mr. Michael H. Carrel
Chief Executive Officer, President & Director
Mr. Douglas J. Seith
Chief Operating Officer
Mr. Karl S. Dahlquist CCEP, J.D.
Chief Legal Officer
Dr. Vinayak Doraiswamy Ph.D.
Chief Scientific Officer
Valerie Storch-Willhaus
Vice President of Corporate Marketing & Communications